$48B Cell therapy market 2030 6 CAR-T FDA-approved products REMS programs Required for all CAR-T Specialty pharmacy Distribution channels $373K-$530K List prices per treatment Outcomes-based Value contracts emerging $48B Cell therapy market 2030 6 CAR-T FDA-approved products REMS programs Required for all CAR-T Specialty pharmacy Distribution channels $373K-$530K List prices per treatment Outcomes-based Value contracts emerging
Prescription Cell Therapy

Living Drugs by Prescription

T cell therapeutics are redefining what a prescription means. From autologous CAR-T to allogeneic off-the-shelf products, cell therapies require new paradigms for ordering, manufacturing, administering, and monitoring.

Acquire Domain View Pipeline
Rx CAR-T PRODUCT NDC LOT# PATIENT Order Track
$48B
Cell Therapy Market 2030
6
FDA-Approved CAR-T Products
80%+
Complete Response Rates
400+
Cell Therapy Clinical Trials

The T Cell Rx Pipeline

From approved products to next-generation platforms

💉

Autologous CAR-T

Patient's own T cells engineered with chimeric antigen receptors. Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti are FDA-approved for blood cancers.

📦

Allogeneic CAR-T

Off-the-shelf donor T cells engineered for universal use. CRISPR-edited to avoid graft-versus-host disease. Allogene, CRISPR Tx, and Precision leading development.

🎯

TCR Therapies

T cell receptors targeting intracellular tumor antigens. Adaptimmune's TECELRA (afamitresgene autoleucel) first TCR-T approved for solid tumors.

🔬

TIL Therapy

Tumor-infiltrating lymphocytes expanded and reinfused. Iovance's Lifileucel for melanoma. Natural tumor-reactive T cells without genetic engineering.

🧬

Solid Tumor CAR-T

Next frontier targeting GD2, mesothelin, claudin18.2, and other solid tumor antigens. Armored CARs and logic-gated designs overcoming tumor microenvironment.

💡

Autoimmune CAR-T

CD19 CAR-T showing remarkable efficacy in lupus and other autoimmune diseases. Potential for drug-free remissions with single treatment courses.

Commercial T Cell Products

FDA-approved cellular therapeutics on the market

Product Company Target Indication List Price
Kymriah Novartis CD19 B-ALL, DLBCL, FL $373K-$475K
Yescarta Kite/Gilead CD19 LBCL, FL $424K
Tecartus Kite/Gilead CD19 MCL, B-ALL $373K
Breyanzi BMS/Juno CD19 LBCL, FL, MCL, CLL $410K
Abecma BMS/2seventy BCMA Multiple Myeloma $419K
Carvykti J&J/Legend BCMA Multiple Myeloma $465K
Tecelra Adaptimmune MAGE-A4 (TCR) Synovial Sarcoma $727K
Amtagvi Iovance TIL Melanoma $515K

Own the T Cell Rx Brand

TcellRx.com - Premium domain for the cell therapy pharmaceutical space. Ideal for specialty pharmacy, distribution, or therapeutic platforms.

Contact for Pricing
Acquire This Domain

Own Tcellrx

This premium domain is available for acquisition. Perfect for companies, startups, or investors in this space.

Submit your inquiry below and we'll respond within 24 hours.